Immunic, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMUX research report →
About the company
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease.
- CEO
- Daniel Vitt
- IPO
- 2014
- Employees
- 91
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $146.05M
- P/E
- -2.47
- P/S
- 0.00
- P/B
- 2.95
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -220.75%
- ROIC
- -72.29%
- Revenue
- $0 · 0.00%
- Net Income
- $-97,172,000 · 3.32%
- EPS
- $-6.24 · 37.60%
- Op Income
- $-103,228,000
- FCF YoY
- -1.10%
- 52W High
- $15.84
- 52W Low
- $5.06
- 50D MA
- $12.75
- 200D MA
- $9.53
- Beta
- 1.39
- Avg Volume
- 271.33K
Get TickerSpark's AI analysis on IMUX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Congleton Jon | other | 50,740 |
| Jun 29, 26 | Skerjanec Simona | other | 25,370 |
| Jun 29, 26 | Rudick Richard Alan | other | 25,370 |
| Jun 29, 26 | HOWSON TAMAR D | other | 25,370 |
| Jun 29, 26 | Neermann Joerg | other | 25,370 |
| Jun 29, 26 | PHILLIPS BARCLAY A | other | 25,370 |
| Jun 29, 26 | Tardio Jason | other | 253,000 |
| Jun 29, 26 | Whaley Glenn | other | 120,000 |
| Jun 29, 26 | Vitt Daniel | other | 445,000 |
| Jun 29, 26 | BONNEY MICHAEL W | other | 100,000 |
Our IMUX coverage
Recent articles, reports, and earnings notes.
No research on IMUX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMUX report →Similar companies
Peers in the same neighborhood.